We are pleased to announce our investment in LYLA, a medtech startup that helps curing cancer through transforming quality control (QC) of radiopharmaceuticals. Radiopharmaceuticals are an emerging cancer treatment with high potential, but their widespread adoption is hindered by quality control. LYLA’s compact scanner streamlines the QC workflow of this next-generation cancer therapy, making it more accessible and reliable.

‍

Radiopharmaceuticals offer a promising treatment for metastatic cancers, targeting cancer cells while sparing healthy tissue. However, current QC methods are inefficient, requiring a four-hour waiting period to measure isotope effectiveness, reducing treatment potency. This delay complicates scheduling and limits flexibility. Additionally, existing QC technologies are unsuitable for newer therapies like Target Alpha Therapy (TAT), leading to unreliable results.

‍

To overcome these challenges, LYLA is developing a compact, automated scanner that radically simplifies and accelerates QC for radiopharmaceuticals. Their patented technology, developed in collaboration with TU Delft and Erasmus MC, reduces QC time from four hours to just ten minutes. This allows for more accurate QC, resulting in improved treatments, and significantly reduces the operational burden on hospitals. Unlike traditional systems, LYLA’s scanner is designed to be compatible with next-generation therapies like Target Alpha Therapy (TAT), offering accurate, reproducible results without the need for fume hoods or specialized infrastructure. By reducing complexity, cost, and radiation exposure, LYLA’s solution makes advanced cancer treatments with radiopharmaceuticals accessible and reliable worldwide.

‍

Co-founders Ernst van der Wal, Bauke van Gameren, and Kas Hogeboom each bring deep expertise in hardware, software, and business respectively. Their complementary strengths come together with a shared vision to drive meaningful impact in the global fight against cancer.

‍

At Graduate Entrepreneur, we believe in the power of innovation to solve critical challenges. We are proud to support LYLA in their mission to relieve pressure on hospitals and accelerate access to life-saving radiopharmaceutical cancer therapies.

‍

Interested in learning more about LYLA? Check out their website!

‍